JP2018502112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502112A5 JP2018502112A5 JP2017534822A JP2017534822A JP2018502112A5 JP 2018502112 A5 JP2018502112 A5 JP 2018502112A5 JP 2017534822 A JP2017534822 A JP 2017534822A JP 2017534822 A JP2017534822 A JP 2017534822A JP 2018502112 A5 JP2018502112 A5 JP 2018502112A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- therapeutic agent
- aav
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098085P | 2014-12-30 | 2014-12-30 | |
| US62/098,085 | 2014-12-30 | ||
| PCT/US2015/068034 WO2016109649A1 (en) | 2014-12-30 | 2015-12-30 | Methods and compositions for treating brain diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502112A JP2018502112A (ja) | 2018-01-25 |
| JP2018502112A5 true JP2018502112A5 (https=) | 2019-02-07 |
| JP6782701B2 JP6782701B2 (ja) | 2020-11-11 |
Family
ID=56285031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534822A Active JP6782701B2 (ja) | 2014-12-30 | 2015-12-30 | 脳疾患を処置するための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11612641B2 (https=) |
| EP (1) | EP3240577B1 (https=) |
| JP (1) | JP6782701B2 (https=) |
| KR (1) | KR102618947B1 (https=) |
| CN (1) | CN107405414A (https=) |
| AU (1) | AU2015374043B2 (https=) |
| BR (1) | BR112017013674A2 (https=) |
| CA (1) | CA2971687C (https=) |
| ES (1) | ES2962439T3 (https=) |
| SG (1) | SG11201704829QA (https=) |
| WO (1) | WO2016109649A1 (https=) |
| ZA (1) | ZA201704327B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016077687A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| EP3240577B1 (en) | 2014-12-30 | 2023-07-05 | University of Iowa Research Foundation | Therapeutic agent that activates mtorc1 function for use in treating huntington's disease |
| KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| KR102427379B1 (ko) | 2016-05-18 | 2022-08-02 | 보이저 테라퓨틱스, 인크. | 헌팅톤 질환을 치료하기 위한 조성물 및 방법 |
| CL2016003282A1 (es) * | 2016-12-21 | 2017-08-18 | Univ Chile | Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington |
| WO2018132791A1 (en) | 2017-01-16 | 2018-07-19 | The Regents Of The University Of California | Treatment of neurodegenerative conditions by disruption of rhes |
| JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハンチントン病治療組成物および方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050255086A1 (en) | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
| US20050009112A1 (en) | 2003-03-07 | 2005-01-13 | Fred Hutchinson Cancer Research Center, Office Of Technology Transfer | Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth |
| CA2606226A1 (en) | 2005-04-27 | 2006-11-02 | University Of Florida Research Foundation, Inc. | Materials and methods for enhanced degradation of mutant proteins associated with human disease |
| KR101286870B1 (ko) * | 2009-11-30 | 2013-07-16 | (주)아모레퍼시픽 | 황기 추출물을 포함하는 대사 촉진 조성물 |
| PT2771342T (pt) * | 2011-10-28 | 2016-08-17 | Novartis Ag | Derivados de purina e o seu uso no tratamento de doença |
| EP2773382A4 (en) * | 2011-11-01 | 2016-03-23 | Childrens Medical Center | SIMULTANEOUS ACTIVATION OF MTOR AND STAT3 PATHS TO PROMOTE NEURONAL SURVIVAL AND REGENERATION |
| WO2013070976A1 (en) * | 2011-11-08 | 2013-05-16 | Intellikine, Llc | Treatment regimens using multiple pharmaceutical agents |
| US9095521B2 (en) * | 2012-02-02 | 2015-08-04 | Washington University | Methods for improving muscle strength |
| KR101626526B1 (ko) | 2014-10-30 | 2016-06-02 | 경북대학교 산학협력단 | ｈＲｈｅｂ를 유효성분으로 포함하는 허혈성 뇌질환의 예방 또는 치료용 조성물 |
| EP3240577B1 (en) | 2014-12-30 | 2023-07-05 | University of Iowa Research Foundation | Therapeutic agent that activates mtorc1 function for use in treating huntington's disease |
-
2015
- 2015-12-30 EP EP15876243.5A patent/EP3240577B1/en active Active
- 2015-12-30 SG SG11201704829QA patent/SG11201704829QA/en unknown
- 2015-12-30 CN CN201580077153.9A patent/CN107405414A/zh active Pending
- 2015-12-30 CA CA2971687A patent/CA2971687C/en active Active
- 2015-12-30 ES ES15876243T patent/ES2962439T3/es active Active
- 2015-12-30 KR KR1020177020915A patent/KR102618947B1/ko active Active
- 2015-12-30 US US15/540,746 patent/US11612641B2/en active Active
- 2015-12-30 BR BR112017013674A patent/BR112017013674A2/pt not_active Application Discontinuation
- 2015-12-30 AU AU2015374043A patent/AU2015374043B2/en active Active
- 2015-12-30 WO PCT/US2015/068034 patent/WO2016109649A1/en not_active Ceased
- 2015-12-30 JP JP2017534822A patent/JP6782701B2/ja active Active
-
2017
- 2017-06-26 ZA ZA2017/04327A patent/ZA201704327B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502112A5 (https=) | ||
| JP2020514286A5 (https=) | ||
| JP2014512171A5 (https=) | ||
| JP2017513504A5 (https=) | ||
| JP2021530548A (ja) | 遺伝子治療製剤を生産するための系および方法 | |
| JP2018520646A5 (https=) | ||
| JP2019513779A5 (https=) | ||
| JP2016500519A5 (https=) | ||
| Ozlu et al. | Gene transfer therapy for neurodevelopmental disorders | |
| JP2019504003A5 (https=) | ||
| RU2021134920A (ru) | Композиции и способы деградации неправильно упакованных белков | |
| PH12021552887A1 (en) | Modified viral particles and uses thereof | |
| JP2016523956A5 (https=) | ||
| EA201491081A1 (ru) | Композиции и способы для лечения заболеваний и расстройств печени | |
| JP2019523648A5 (https=) | ||
| JP2020537637A5 (https=) | ||
| JP2014526904A5 (https=) | ||
| JP2017518316A5 (https=) | ||
| Bhat et al. | Therapeutic approaches targeting aging and cellular senescence in Huntington's disease | |
| EA202091194A1 (ru) | Вирусные векторы, содержащие области, кодирующие rdh12, и способы лечения дистрофий сетчатки | |
| JP2018509154A5 (https=) | ||
| FI3737423T3 (fi) | Koostumuksia ja menetelmiä verkkokalvon häiriöiden hoitoon | |
| JP2023542950A (ja) | α－シヌクレインの凝集を阻害するための組成物及び方法 | |
| Duan et al. | Deaths in gene therapy of Duchenne muscular dystrophy and other diseases: underlying mechanisms and mitigating strategies | |
| Ketterl et al. | Ofatumumab for refractory opsoclonus‐myoclonus syndrome following treatment of neuroblastoma |